EP1896856A1 - Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce - Google Patents

Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce

Info

Publication number
EP1896856A1
EP1896856A1 EP06763931A EP06763931A EP1896856A1 EP 1896856 A1 EP1896856 A1 EP 1896856A1 EP 06763931 A EP06763931 A EP 06763931A EP 06763931 A EP06763931 A EP 06763931A EP 1896856 A1 EP1896856 A1 EP 1896856A1
Authority
EP
European Patent Office
Prior art keywords
markers
rejection
sample
marker
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06763931A
Other languages
German (de)
English (en)
Inventor
Harald Mischak
Stefan Wittke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Priority to EP06763931A priority Critical patent/EP1896856A1/fr
Publication of EP1896856A1 publication Critical patent/EP1896856A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Definitions

  • the present invention relates to the use of the presence or absence of one or more peptide markers in a sample of an individual for the early detection of rejection (rejection) of transplanted kidneys and a method for early detection of rejection of transplanted kidneys, wherein the presence or absence of the or the peptide marker (s) is indicative of the presence of kidney transplant rejection (NTx).
  • NTx kidney transplant rejection
  • Kidney transplantation is the most commonly performed organ transplantation in Germany. The waiting time for a new kidney is still around 6-8 years.
  • the goal of therapy after successful kidney transplantation (NTx) is to maintain functional capability over the longest possible period and to prevent rejection of the transplant (rejection). On average, 10-15% of organs lose NTx from various complications. A timely detection of the onset of rejection is therefore extremely important, since it must be immediately intervened with medication to obtain the graft.
  • an object of the present invention is the use of the presence or absence and amplitude of at least one polypeptide marker in an individual's sample for detecting rejection of transplanted kidney, wherein the polypeptide marker is selected from polypeptide labels Nos. 1 to 767, the characterized by the molecular masses given in Table 1 and their migration times.
  • Table 1 Polypeptide marker for detecting the rejection of transplanted kidneys and their molecular masses (in Da) and migration times (CE time in minutes):
  • the present invention it is possible to diagnose the rejection very early. As a result, the onset of rejection can be treated with medication at an early stage.
  • the invention further enables cost-effective, rapid and reliable detection of the rejection by means of interventions that are in part not or only minimally invasive.
  • the migration time is determined by means of capillary electrophoresis (CE), as described in Example 2, for example.
  • CE capillary electrophoresis
  • a 90 cm long glass capillary with an inner diameter (ID) of 50 microns and an outer diameter (OD) of 360 microns at an applied voltage of 25 or 30 kV operated.
  • the eluent used is 30% methanol, 0.5% formic acid or 20% acetonitrile and 0.25 M formic acid in water.
  • CE migration time can vary. Nevertheless, the order in which the polypeptide labels elute is typically the same for each CE system used under the conditions indicated. To even out any differences in migration time, the system can be normalized using standards for which migration times are known. These standards may e.g. be the polypeptides given in the examples (see example point 3).
  • the characterization of the polypeptides shown in Tables 1 to 2 was determined by capillary electrophoresis mass spectrometry (CE-MS), a method which was described e.g. in detail by Neuhoff et al. (Rapid Communications in mass spectrometry, 2004, Vol. 20, pages 149-156).
  • CE-MS capillary electrophoresis mass spectrometry
  • the variation of molecular masses between individual measurements or between different mass spectrometers is relatively small with exact calibration, typically in the range of ⁇ 0.1%, preferably in the range of ⁇ 0.05%, more preferably ⁇ 0.03%.
  • polypeptide markers according to the invention are proteins or peptides or degradation products of proteins or peptides. They may be chemically modified, e.g. by post-translational modifications such as glycation, phosphorylation, alkylation or disulfide bridging, or by other reactions, e.g. in the context of mining, to be changed. In addition, the polypeptide markers may also be chemically altered as part of the purification of the samples, e.g. oxidized, be.
  • polypeptide markers Based on the parameters that determine the polypeptide markers (molecular mass and migration time), it is possible to identify the sequence of the corresponding polypeptides by methods known in the art.
  • the polypeptides of the invention are used to diagnose incipient rejection of the graft. Diagnosis is the process of gaining knowledge by assigning symptoms or phenomena to a disease or injury. In the present case, the presence or absence or differences in the amplitude of certain polypeptide markers implies rejection.
  • the polypeptide markers according to the invention are determined in a sample of an individual, their presence or absence and their signal intensity / amplitude suggesting the presence of a rejection. The presence or absence and amplitude of a polypeptide marker can be measured by any method known in the art. Methods that can be used are exemplified below.
  • a polypeptide marker is present when its reading is at least as high as the threshold. If its reading is below that, the polypeptide marker is absent.
  • the threshold value can either be determined by the sensitivity of the measurement method (detection limit) or defined based on experience.
  • the threshold is preferably exceeded when the sample reading for a given molecular mass is at least twice that of a blank (e.g., only buffer or solvent).
  • the polypeptide marker (s) is / are used to measure its presence or absence, the presence or absence being indicative of rejection (frequency marker # 1 - # 242, Table 2).
  • polypeptide markers that are typically present in patients after renal transplantation (NTx) and rejection, such as polypeptide markers Nos. 1-5, but are uncommon in NTx patients but without rejection (control).
  • polypeptide markers which are frequently present in patients without rejection but which occur less frequently or not at all in patients with rejection eg 6 to 15 (Table 2).
  • the amplitude markers indicated in Tables 3 and 4 can also be used to diagnose renal transplant rejections (Numbers 243-767). Amplitude markers are used in a manner that does not determine the presence or absence, but decides the magnitude of the signal (amplitude) in the presence of the signal in both groups. Two standardization methods are possible in order to achieve comparability between differently concentrated samples or different measurement methods: In the first approach, all peptide signals of a sample are normalized to a total ampli- tude of 1 million counts. The respective mean amplitudes of the individual markers are therefore given as parts per million (ppm). The amplitude markers resulting from this procedure are shown in Table 3 (number 243-627). In addition, it is possible to define additional amplitude markers via an alternative standardization procedure:
  • all peptide signals of a sample are scaled with a common normalization factor.
  • a linear regression is formed between the peptide amplitudes of the individual samples and the reference values of known polypeptides in the sample.
  • the slope of the regression line just corresponds to the relative concentration and is used as a normalization factor for this sample.
  • the markers characterized by this method are shown in Table 4.
  • All groups used consist of at least 19, preferably at least 20 individual patient or control samples to obtain a reliable mean amplitude.
  • the decision to make a diagnosis will depend on how high the amplitude of the respective polypeptide markers in the patient sample is compared to the mean amplitudes in the control group or rejection group. If the amplitude corresponds more closely to the mean amplitudes of the rejection group, it can be assumed that the kidney transplant is rejected and corresponds more closely to the mean amplitudes of the control group; it can not be assumed to be a rejection. A more precise definition should be given using marker no. 247 (Table 3).
  • the mean amplitude of the marker is markedly increased upon rejection of the kidney transplant (654 ppm versus 75 ppm in the group without rejection). If the value for this marker is 0 to 75 ppm in a patient sample, or a maximum of 20% above this, ie 0 to 90 ppm, this sample belongs to the control group without rejection. If the value is 654 ppm, or 20% lower, or higher, ie between 523 ppm and very high values, rejection after kidney transplantation can be assumed. Table 3: Amplitude markers (ppm normalization)
  • the individual from whom the sample is derived, in which the presence or absence and the amplitude of one or more polypeptide markers is determined may be any individual who may suffer from a rejection to NTx, e.g. an animal or a human.
  • the subject is a mammal, most preferably a human.
  • not only a polypeptide marker but a combination of markers is used to diagnose NTx rejection. Their presence or absence, as well as differences in amplitude, indicate the presence of a rejection after NTx closed.
  • the falsification of the overall result can be reduced or avoided by individual individual deviations from the typical probability of presence in the patient or control individual.
  • the sample measuring the presence or absence as well as the amplitude of the polypeptide marker (s) of the invention may be any sample recovered from the subject's body.
  • the sample is a sample that has a polypeptide composition suitable for making statements about the condition of the individual (rejection to NTx or not).
  • it may be blood, urine, synovial fluid, tissue fluid, body secretions, sweat, cerebrospinal fluid, lymph, intestinal, gastric, pancreatic, bile, tears, tissue, sperm, vaginal fluid, or a stool sample.
  • it is a liquid sample.
  • the sample is a urine sample or a blood sample, where a blood sample may be a serum (blood) or plasma (blood) sample.
  • Urine samples may be known as known in the art.
  • a mid-jet urine sample is used.
  • the urine sample may e.g. by means of a catheter or also with the aid of a urination apparatus, as described in WO 01/74275.
  • Blood samples may be taken by methods known in the art, for example from a vein, artery or capillary.
  • a blood sample is obtained by removing venous blood from an individual, for example, from the arm by means of a syringe.
  • the term blood sample also includes samples obtained from blood by further purification and separation techniques known in the art, such as blood plasma or blood serum.
  • the presence or absence and amplitude of a polypeptide marker in the sample can be determined by any method known in the art suitable for measuring polypeptide markers. Those skilled in such methods are known. In principle, the presence or absence and the amplitude of a polypeptide marker can be determined by direct methods, such as, for example, mass spectrometry, or indirect methods, such as, for example, by means of ligands.
  • the sample of the individual e.g. the urine or blood sample
  • the treatment may e.g. a purification, separation, dilution or concentration.
  • the methods may be, for example, centrifugation, filtration, ultrafiltration, dialysis, precipitation or chromatographic methods such as affinity separation or separation by means of ion exchange chromatography, or an electrophoretic separation.
  • the sample is separated by electrophoresis prior to its measurement, purified by ultracentrifugation and / or separated by ultrafiltration into fractions containing polypeptide labels of a specific molecular size.
  • a mass spectrometric method is used to determine the presence or absence and amplitude of a polypeptide marker, which method can be preceded by a purification or separation of the sample.
  • the mass spectrometric analysis has the advantage over current methods that the concentration of many (> 100) polypeptides of a sample can be determined by a single analysis. Any type of mass spectrometer can be used.
  • mass spectrometry it is possible to routinely measure 10 fmoles of a polypeptide marker, ie 0.1 ng of a 10 kDa protein with a measurement accuracy of approximately ⁇ 0.01% from a complex mixture.
  • an ion-forming unit is coupled to a suitable analyzer.
  • electrospray ionization (ESI) interfaces are most commonly used to measure ions from liquid samples, whereas the matrix assisted laser desorption / ionization (MALDI) technique is used to measure ions from sample crystallized with a matrix.
  • MALDI matrix assisted laser desorption / ionization
  • quadrupoles, ion traps or time-of-flight (TOF) analyzers can be used to analyze the resulting ions.
  • electrospray ionization the molecules present in solution i.a. is sprayed under the influence of high voltage (e.g., 1-8 kV) to form charged droplets, which become smaller due to evaporation of the solvent.
  • high voltage e.g. 1-8 kV
  • Coulomb explosions lead to the formation of free ions, which can then be analyzed and detected.
  • TOF analyzers have a very high scanning speed and achieve a very high resolution.
  • Preferred methods for determining the presence or absence and amplitude of polypeptide markers include gas phase ion spectrometry, such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (surface enhanced laser desorption ionization), LC-MS ( Liquid chromatography mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • gas phase ion spectrometry such as laser desorption / ionization mass spectrometry, MALDI-TOF-MS, SELDI-TOF-MS (surface enhanced laser desorption ionization), LC-MS ( Liquid chromatography mass spectrometry), 2D-PAGE-MS and capillary electrophoresis mass spectrometry (CE-MS). All of the methods mentioned are known to the person skilled in the art.
  • CE-MS in which capillary electrophoresis is coupled with mass spectrometry. This process is described in detail, for example, in German patent application DE 10021737, in Kaiser et al. (J. Chromatogr. A 1 2003, Vol. 1013: 157-171, and Electrophoresis, 2004, 25: 2044-2055) and in Wittke et al. (J. Chromatogr. A 1 2003, 1013: 173-181 and Electrophoresis, 2005, 26 (7-8): 1476-87).
  • the CE-MS technique allows the presence and amplitude of several hundred polypeptide markers of a sample to be determined simultaneously in a short time, with a low volume and high sensitivity.
  • a pattern of the measured polypeptide markers is prepared. This can be compared with reference patterns of ill or healthy individuals. In most cases, it will be sufficient to use a limited number of polypeptide markers to detect rejection of NTx. More preferred is a CE-MS method which includes CE coupled online to an ESI-TOF-MS.
  • solvents for CE-MS, the use of volatile solvents is preferred, and it is best to work under essentially salt-free conditions.
  • suitable solvents include acetonitrile, methanol and the like.
  • the solvents may be diluted with water and treated with a weak acid (e.g., 0.1% to 1% formic acid) to protonate the analyte, preferably the polypeptides.
  • Capillary electrophoresis makes it possible to separate molecules according to their charge and size. Neutral particles migrate at the rate of electro-osmotic flow when creating a current, cations are accelerated and anions delayed.
  • the advantage of capillaries in electrophoresis is the favorable surface-to-volume ratio, which enables a good removal of the Joule heat arising during the current flow. This in turn allows the application of high voltages (usually up to 30 kV) and thus a high separation efficiency and short analysis times.
  • quartz glass capillaries with internal diameters of typically 50 to 75 ⁇ m are normally used. The used lengths are 30-100 cm.
  • the capillaries usually consist of plastic-coated quartz glass.
  • the capillaries may be both untreated, i. on the inside show their hydrophilic groups, as well as be coated on the inside. A hydrophobic coating can be used to improve the resolution.
  • a pressure which is typically in the range of 0-1 psi may also be applied. The pressure can also be created during the separation or changed during the process.
  • the markers of the sample are separated by capillary electrophoresis, then directly ionized and transferred online to a mass spectrometer coupled thereto for detection.
  • polypeptide markers can be used to detect a rejection of NTx in the method according to the invention.
  • at least three polypeptide markers may be used, for example, markers 1, 2 and 3; 1, 2 and 4; etc.
  • Urine was used to detect polypeptide markers for the detection of NTx rejection. Urine was collected from patients after NTx with rejection and from patients after NTx without rejection (control group).
  • the proteins also present in urine of patients in higher concentration such as albumin and immunoglobulins were separated by ultrafiltration.
  • 700 .mu.l urine were removed and treated with 700 ml_ filtration buffer (2M urea, 1OmM ammonia, 0.02% SDS). These 1.4 ml sample volumes were ultrafiltered (20 kDa, Sartorius, Göttingen, Germany). The UF was carried out at 3000 rpm in a centrifuge until 1.1 ml ultrafiltrate was obtained.
  • CE-MS measurements were carried out using a Beckman Coulter capillary electrophoresis system (P / ACE MDQ system, Beckman Coulter Ine, Fullerton, USA) and Bruker ESI-TOF mass spectrometer (micro-TOF MS, Bruker Daltonik, Bremen, D).
  • the CE capillaries were purchased from Beckman Coulter, having an ID / OD of 50/360 ⁇ m and a length of 90 cm.
  • the mobile phase for the CE separation consisted of 20% acetonitrile, 0.25 M formic acid in water. 30% isopropanol with 0.5% formic acid was used for the "sheath flow" on the MS, here with a flow rate of 2 ⁇ l / min.
  • the coupling of CE and MS was performed by a CE-ESI-MS sprayer kit (Agilent Technologies , Waldbronn, DE).
  • the duration of the injection was 99 seconds. With these parameters about 150 nl of the sample were injected into the capillary, this corresponds to about 10% of the capillary volume.
  • a "stacking" technique was used, injecting an IM NH 3 solution for 7 sec (at 1 psi) before injecting the sample and injecting a 2M formic acid solution for 5 sec after sample injection the separation voltage (25 kV), the analytes are automatically concentrated between these solutions.
  • CE separation was performed with a pressure method: 0 psi for 40 minutes, 0.1 psi for 2 minutes, 0.2 psi for 2 minutes, 0.3 psi for 2 minutes, 0.4 psi for 2 minutes, finally 32 min at 0.5 psi.
  • the total duration of a separation run was thus 80 minutes.
  • the "Nebulizer gas” was set to the lowest possible value.
  • the voltage applied to the spray needle to generate the electrospray was 3700 - 4100 V.
  • the other settings on the mass spectrometer were made as instructed The spectra were recorded over a mass range from m / z 400 to m / z 3000 and accumulated every 3 seconds.
  • ELM sequence: ELMTGELPYSHINNRDQIIFMVGR 23.4 min
  • the proteins / polypeptides are each used in a concentration of 10 pmol / ⁇ l in water. "RE ⁇ T,” ELM “,” KINCON “and” GIVLY "represent synthetic peptides.

Abstract

L'invention concerne un procédé pour détecter un rejet après une greffe de rein (NTx). Ce procédé comprend l'étape qui consiste à déterminer la présence ou l'absence d'au moins un marqueur polypeptidique (marqueur de fréquence) dans un échantillon, ou à déterminer l'amplitude d'au moins un marqueur polypeptidique (marqueur d'amplitude) qui est caractérisé par des valeurs de masse moléculaire et de temps de migration (CE-Zeit).
EP06763931A 2005-06-29 2006-06-28 Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce Withdrawn EP1896856A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06763931A EP1896856A1 (fr) 2005-06-29 2006-06-28 Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05105822 2005-06-29
DE102005058514 2005-12-08
EP05112767 2005-12-22
EP06763931A EP1896856A1 (fr) 2005-06-29 2006-06-28 Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
PCT/EP2006/063635 WO2007000466A1 (fr) 2005-06-29 2006-06-28 Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce

Publications (1)

Publication Number Publication Date
EP1896856A1 true EP1896856A1 (fr) 2008-03-12

Family

ID=36933512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06763931A Withdrawn EP1896856A1 (fr) 2005-06-29 2006-06-28 Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce

Country Status (4)

Country Link
US (2) US20100200401A1 (fr)
EP (1) EP1896856A1 (fr)
JP (1) JP5155857B2 (fr)
WO (1) WO2007000466A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012306A1 (fr) * 2008-07-31 2010-02-04 Queen Mary And Westfield College, University Of London Biomarqueurs pour rein sain
CA2770189A1 (fr) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methodes et dispositifs permettant de detecter le rejet d'une greffe renale
JP6842195B2 (ja) 2016-12-19 2021-03-17 国立大学法人大阪大学 インビトロでのＩｇＭ型メモリーＢ細胞分化培養系を用いた臓器移植後抗体関連型拒絶反応の早期診断法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340721A (en) * 1991-07-26 1994-08-23 Board Of Regents, The University Of Texas System Assay for free secretory component and methods for monitoring organ rejection
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007000466A1 *

Also Published As

Publication number Publication date
WO2007000466A1 (fr) 2007-01-04
JP5155857B2 (ja) 2013-03-06
JP2008545130A (ja) 2008-12-11
US20100200401A1 (en) 2010-08-12
US20150126405A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
EP1757939A1 (fr) Marqueurs polypeptidiques pour la diagnose du cancer de la vessie
EP2255203A2 (fr) Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
WO2010031822A1 (fr) Carcinome à cellules rénales
EP1287348A2 (fr) Procede et dispositif de determination qualitative et/ou quantitative d'un modele proteique et/ou peptidique d'un echantillon de liquide, preleve d'un corps humain ou animal
EP1955064A1 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
WO2008110593A2 (fr) Procédé et marqueurs pour le diagnostic de maladies rénales
WO2006106129A2 (fr) Marqueurs polypeptidiques pour diagnostiquer le cancer de la prostate
WO2011000938A1 (fr) Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë
WO2009047280A2 (fr) Marqueur polypeptidique pour le diagnostic du cancer de la prostate
EP2212703A1 (fr) Procédé et marqueurs pour diagnostiquer le diabète sucré
EP2478377A2 (fr) Polypeptide marqueur pour le diagnostic et l'évaluation de maladies vasculaires
WO2010079076A2 (fr) Maladie polykystique rénale autosomique dominante (adpkd)
EP2810077A2 (fr) Marqueurs polypeptidiques pour le diagnostic et l'évaluation de l'insuffisance cardiaque
WO2007000466A1 (fr) Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
EP1784649B1 (fr) Marqueurs polypeptidiques pour le diagnostic de l'arteriosclerose
WO2006106115A2 (fr) Marqueur de polypeptide pour le diagnostic d'alzheimer
EP2649450A1 (fr) Procédé et marqueur pour le diagnostic d'un rétrécissement des voies biliaires et d'un cholangiocarcinome à partir de la bile
WO2007063089A2 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer des maladies vasculaires
WO2012123527A1 (fr) Procédé et marqueurs de diagnostic de formes infracliniques et cliniques du rejet tubulo-interstitiel à médiation lymphocytaire t après une transplantation rénale
WO2013150132A2 (fr) Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: WITTKE, STEFAN

Inventor name: MISCHAK, HARALD

17Q First examination report despatched

Effective date: 20080424

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1112758

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1112758

Country of ref document: HK